Specifica Reaches Antibody Discovery Platform Transfer Agreement with Sanofi
Specifica, a privately held antibody engineering company focused on innovative in vitro antibody discovery tools and libraries, has reached an antibody discovery platform transfer agreement with the global healthcare company Sanofi.
In this agreement, Specifica’s Generation 3 Antibody Discovery platform will be transferred to Sanofi. This will enable the integration of Specifica’s Gen 3 platform into Sanofi’s antibody discovery programs.
What does this platform do? Specifica’s Gen 3 libraries combine clinically validated antibody frameworks with compatible binding loop sequences from natural human antibodies that have been purged of sequence-based developability liabilities.
Specifica CEO Ken Sharples has said that the partnership with Sanofi will provide a “complete antibody discovery platform through a combination of Gen 3 libraries, antibody optimization solutions, and integrated discovery tools.”
Specifica is a start up company in New Mexico that was originally supported by the New Mexico Consortium.
Read more on Specifica’s News Page.